Seer, Inc.

NASDAQ•SEER

CEO: Dr. Omid C. Farokhzad M.D., Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2020-12-04

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

联系方式

3800 Bridge Parkway, Suite 102, Redwood City, CA, 94065, United States

650-453-0000

seer.bio

市值

$104.07M

市盈率 (TTM)

-1.4

19.7

股息率

52周最高

$2.41

52周最低

$1.62

52周范围

29%

排名54Top 78.1%

2.7

F-Score

改良版 Piotroski 分析

基于 7 年期基本面

疲弱 • 2.7 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2019-2025

财务仪表盘

Q4 2025 数据

营业收入

$4.20M+0.00%

近4季度走势

每股收益

-$0.29+0.00%

近4季度走势

自由现金流

-$11.10M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Total Revenue Increased 17% Total revenue reached $16.6M in 2025, up 17% ($2.4M increase), driven by higher product sales and service revenue.

Gross Profit and Loss Improvement Gross profit grew 20% to $8.5M; Net loss improved 15% to $(73.6M), reflecting reduced operating expenses.

Operating Expenses Significantly Reduced Total operating expenses decreased 19% to $86.5M, primarily due to 25% reduction in SG&A expenses ($14.0M decrease).

Proteograph ONE Throughput Gains Third-generation Proteograph ONE assay launched in May 2025, delivering 3.6x throughput increase over previous assay versions.

关注风险

Continued Operating Losses Expected Company has incurred significant losses since 2017; expects to continue incurring net losses and negative cash flows near term.

Market Acceptance Uncertainty Commercial success hinges on broad scientific and market acceptance of Proteograph, which may take longer than anticipated.

Intellectual Property Enforcement Risk Reliance on patents; challenges or failure to enforce IP rights could allow competitors to commercialize similar products.

Reliance on Key Customers Related party revenue was 5% of total revenue in 2025; loss of key customers could materially impact financial results.

前瞻展望

Drive Installed Base Utilization Focus on driving higher utilization and consumable pull-through from the rapidly expanding installed base across all customer types.

Expand Population-Scale Cohorts Announced several population-scale studies in 2025; actively discussing expansion with additional key biobanks globally.

Leadership in AI Biology Platform Pursue strategic ecosystem partnerships to establish leadership as preferred proteomic data platform for AI-driven discovery.

New Product Innovation Focus Aim to continuously innovate and develop new products, applications, and analysis tools across the R&D value chain.

同行对比

营业收入 (TTM)

GLUE

$181.54M

+1112.3%

NRIX

$83.98M

+54.0%

KYMR

$39.20M

-16.7%

毛利率 (最新季度)

KYMR

2763.6%

-2680.7pp

LYEL

100.0%

+0.0pp

CCCC

83.6%

+13.4pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
KYMR	$6.89B	-23.3	-29.1%	4.7%
PHVS	$1.74B	-8.6	-67.1%	0.2%
NRIX	$1.41B	-5.8	-57.5%	8.1%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

-0.0%

基本持平

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月11日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据